Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $130.00.

Has Gilead Sciences (GILD) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.